Friday, January 22, 2021 1:39:38 PM
The answer to that question is simple, RVVTF has no revenue stream.
They need the money TODAY!
To finish the trial, to run another trial, operating expenses ect.
Plus as others pointed out, this was the M.O. of capitalism by a firm going around to all the companies involved with the Psych ETF.
They need the money TODAY!
To finish the trial, to run another trial, operating expenses ect.
Plus as others pointed out, this was the M.O. of capitalism by a firm going around to all the companies involved with the Psych ETF.
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
